SCHEMBL16640906

SCHEMBL16640906

CCCCCC1(CCCC)NC(=N)N(CC2CCN(C(=O)NCCCC)CC2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.38
TDP1 Q9NUW8 1/20 0.37
BACE1 P56817 2/20 0.35
CTSD P07339 1/20 0.35
MEN1 O00255 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KMT2A Q03164 1/20 0.35
TPSAB1 Q15661 1/20 0.35
TPSD1 Q9BZJ3 1/20 0.35
TPSG1 Q9NRR2 1/20 0.35
POLB P06746 1/20 0.34
MAPK1 P28482 1/20 0.34
NAMPT P43490 2/20 0.33
EPHX2 P34913 2/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7529289 0.98 HTT (0.39) HTTTDP1BACE1CTSDMEN1
SCHEMBL7522795 0.87 KMT2A (0.42) MEN1CNR1CNR2KMT2ATPSAB1
SCHEMBL7529931 0.87 BACE1 (0.40) HTTTDP1BACE1CTSDMEN1
SCHEMBL7523344 0.85 BACE1 (0.40) HTTTDP1BACE1CTSDMEN1
SCHEMBL7525808 0.84 KMT2A (0.34) BACE1CTSDCNR2KMT2AEPHX2
SCHEMBL7529130 0.83 BACE1 (0.34) BACE1CTSDKMT2A
SCHEMBL12173548 0.82 BACE1 (0.33) BACE1CTSDKMT2A
SCHEMBL7529271 0.82 HTT (0.41) HTTTDP1MEN1CNR1CNR2
SCHEMBL7540269 0.81 MEN1 (0.44) HTTMEN1CNR1CNR2KMT2A
SCHEMBL7529054 0.81 HTT (0.37) HTTTDP1BACE1MEN1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9416108-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-9416108-B2 Heterocyclic aspartyl protease inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 US disclosed
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105354-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS PRSS1, BCHE, CTSZ HTT 1558/4885TDP1 369/4885BACE1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.